Reactivation of the Tumour Suppressor RASSF1A in Breast Cancer by Simultaneous Targeting of DNA and E2F1 Methylation

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Montenegro, María F ^a   Sáez Ayala, Magali ^a   Piñero Madrona, Antonio ^b   Cabezas Herrera, Juan ^b   Rodríguez López, José Neptuno ^a  

^a UNIVERSITY OF MURCIA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 O (3,4,5 TRIMETHOXYBENZOYL)CATECHIN; CATECHIN; DIPYRIDAMOLE; DNA; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; DRUG POTENTIATION; DRUG TARGETING; EPIGENETICS; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN METHYLATION; RASSF1A GENE; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CATECHIN; CELL LINE, TUMOR; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; DIPYRIDAMOLE; DNA METHYLATION; DNA, NEOPLASM; DRUG SYNERGISM; E2F1 TRANSCRIPTION FACTOR; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; MCF-7 CELLS; MICE; PROMOTER REGIONS, GENETIC; PROTEIN PROCESSING, POST-TRANSLATIONAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84871294130     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052231     Document Type: Article

References (41)

1. Yang X, Yan L, Davidson NE, (2001) DNA methylation in breast cancer. Endocr Relat Cancer 8: 115-127.
2. Szyf M, (2009) Epigenetics, DNA Methylation, and Chromatin Modifying Drugs. Annu Rev Pharmacol Toxicol 49: 243-263.
3. Issa JPJ, (2007) DNA Methylation as a Therapeutic Target in Cancer. Clin Cancer Res 13: 1634-1637.
4. Ng HH, Bird A, (2000) Histone deacetylases: silencers for hire. Trends Biochemi Sci 25: 121-126.
5. Kawamoto K, Okino ST, Place RF, Urakami S, Hirata H, et al. (2007) Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer. Clin Cancer Res 13: 2541-2548.
6. Kontaki H, Talianidis I, (2010) Lysine methylation regulates E2F1-induced cell death. Mol Cell 39: 152-160.
7. Kontaki H, Talianidis I, (2010) Cross-talk between post-translational modifications regulate life or death decisions by E2F1. Cell Cycle 9: 3836-3837.
8. Sáez-Ayala M, Fernández-Pérez MP, Montenegro MF, Sánchez-del-Campo L, Chazarra S, et al. (2012) Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance. Exp Cell Res 318: 1146-1159.
9. Xie Q, Bai Y, Wu J, Sun Y, Wang Y, et al. (2011) Methylation-mediated regulation of E2F1 in DNA damage-induced cell death. J Recept Signal Transduct Res 31: 139-146.
10. Sanchez-del-Campo L, Rodriguez-Lopez JN, (2008) Targeting the methionine cycle for melanoma therapy with 3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin. Int J Cancer 123: 2446-2455.
11. Sanchez-del-Campo L, Tarraga A, Montenegro MF, Cabezas-Herrera J, Rodriguez-Lopez JN, (2009) Melanoma activation of 3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin to a potent irreversible inhibitor of dihydrofolate reductase. Mol Pharm 6: 883-894.
12. Sáez-Ayala M, Sánchez-del-Campo L, Montenegro MF, Chazarra S, Tárraga A, et al. (2011) Comparison of a pair of synthetic tea-catechin-derived epimers: synthesis, antifolate activity, and tyrosinase-mediated activation in melanoma. ChemMedChem 6: 440-449.
13. Donninger H, Vos MD, Clark GJ, (2007) The RASSF1A tumor suppressor. J Cell Sci 120: 3163-3172.
14. Yan PS, Shi H, Rahmatpanah F, Hsiau TH, Hsiau AH, et al. (2003) Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer. Cancer Res 63: 6178-6186.
15. Jiang Y, Cui L, Chen W-d, Shen S-h, Ding L-d, (2012) The Prognostic Role of RASSF1A Promoter Methylation in Breast Cancer: A Meta-Analysis of Published Data. PLoS ONE 7(5): e36780.
16. Sedelnikova OA, Pilch DR, Redon C, Bonner WM, (2003) Histone H2AX in DNA damage and repair. Cancer Biol Ther 2: 233-235.
17. Tian Y, Hou Y, Zhou X, Cheng H, Zhou R, (2011) Tumor Suppressor RASSF1A Promoter: p53 Binding and Methylation. PLoS ONE 6(2): e17017.
18. Lewis-Wambi JS, Jordan VC, (2009) Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res 11: 206.
19. Louie MC, McClellan A, Siewit C, Kawabata L, (2010) Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance. Mol Cancer Res 8: 343-352.
20. Matallanas D, Romano D, Al-Mulla F, O'Neill E, Al-Ali W, et al. (2011) Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras. Mol Cell 44: 893-906.
21. Liu L, Guo C, Dammann R, Tommasi S, Pfeifer GP, (2008) RASSF1A interacts with and activates the mitotic kinase aurora-A. Oncogene 27: 6175-6186.
22. Dammann R, Li C, Yoon JH, Chin PL, Bates S, et al. (2000) Epigenetic inactivation of a ras association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25: 315-319.
23. Tommasi S, Dammann R, Zhang Z, Wang Y, Liu L, et al. (2005) Tumor susceptibility of Rassf1a knockout mice. Cancer Res 65: 92-98.
24. Campanero MR, Armstrong MI, Flemington EK, (2000) CpG methylation as a mechanism for the regulation of E2F activity. Proc Natl Acad Sci USA 97: 6481-6486.
25. Martínez-Balbás MA, Bauer UM, Nielsen SJ, Brehm A, Kouzarides T, (2000) Regulation of E2F1 activity by acetylation. EMBO J 19: 662-671.
26. Urist M, Tanaka T, Poyurovsky MV, Prives C, (2004) p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev 18: 3041-3054.
27. Lin WC, Lin FT, Nevins JR, (2001) Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev 15: 1833-1844.
28. Chang JW, Hsu HS, Ni HJ, Chuang CT, Hsiung CH, et al. (2010) Distinct epigenetic domains separated by a CTCF bound insulator between the tandem genes, BLU and RASSF1A. PLoS One 5: e12847.
29. Biswas AK, Johnson DG, (2012) Transcriptional and nontranscriptional functions of E2F1 in response to DNA damage. Cancer Res 72: 13-17.
30. Cellarier E, Durando X, Vasson MP, et al. (2003) Methionine dependency and cancer treatment. Cancer Treat Rev 29: 489-499.
31. Winter-Vann AM, Kamen BA, Bergo MO, Young SG, Melnyk S, et al. (2003) Targeting Ras signaling through inhibition of carboxyl methylation: an unexpected property of methotrexate. Proc Natl Acad Sci USA 100: 6529-6534.
32. Copeland RA, Solomon ME, Richon VM, (2009) Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov 8: 724-732.
33. Kurash JK, Lei H, Shen Q, Marston WL, Granda BW, et al. (2008) Methylation of p53 by Set7/9 mediates p53 acetylation and activity in vivo. Mol Cell 29: 392-400.
34. Jenal M, Trinh E, Britschgi C, Britschgi A, Roh V, et al. (2009) The tumor suppressor gene hypermethylated in cancer 1 is transcriptionally regulated by E2F1. Mol Cancer Res 7: 916-922.
35. Matallanas D, Romano D, Yee K, Meissl K, Kucerova L, et al. (2007) RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol Cell 27: 962-975.
36. Guo C, Zhang X, Pfeifer GP, (2011) The tumor suppressor RASSF1A prevents dephosphorylation of the mammalian STE20-like kinases MST1 and MST2. J Biol Chem 286: 6253-6261.
37. Shi Y, (2009) Serine/threonine phosphatases: mechanism through structure. Cell 139: 468-484.
38. De Baere I, Derua R, Janssens V, Van Hoof C, Waelkens E, et al. (1999) Purification of porcine brain protein phosphatase 2A leucine carboxyl methyltransferase and cloning of the human homologue. Biochemistry 38: 16539-16547.
39. Lee J, Chen Y, Tolstykh T, Stock J, (1996) A specific protein carboxyl methylesterase that demethylates phosphoprotein phosphatase 2A in bovine brain. Proc Natl Acad Sci USA 93: 6043-6047.
40. Dorssers LC, Van der Flier S, Brinkman A, van Agthoven T, Veldscholte J, et al. (2001) Tamoxifen resistance in breast cancer: elucidating mechanisms. Drugs 61: 1721-1733.
41. Shevchenko A, Wilm M, Vorm O, Mann M, (1996) Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 68: 850-858.